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Interaction of the Gelsolin-Derived Antibacterial PBP 10 Peptide with
Lipid Bilayers and Cell Membranes
Abstract
PBP 10, an antibacterial, cell membrane-permeant rhodamine B-conjugated peptide derived from the
polyphosphoinositide binding site of gelsolin, interacts selectively with both lipopolysaccharides (LPS) and
lipoteichoic acid (LTA), the distinct components of gram-negative and gram-positive bacteria, respectively.
Isolated LPS and LTA decrease the antimicrobial activities of PBP 10, as well as other antimicrobial peptides,
such as cathelicidin-LL37 (LL37) and mellitin. In an effort to elucidate the mechanism of bacterial killing by
PBP 10, we compared its effects on artificial lipid bilayers and eukaryotic cell membranes with the actions of
the mellitin, magainin II, and LL37 peptides. This study reveals that pore formation is unlikely to be involved
in PBP 10-mediated membrane destabilization. We also investigated the effects of these peptides on platelets
and red blood cells (RBCs). Comparison of these antimicrobial peptides shows that only mellitin has a toxic
effect on platelets and RBCs in a concentration range concomitant with its bactericidal activity. The hemolytic
activities of the PBP 10 and LL37 peptides significantly increase when RBCs are osmotically swollen in
hypotonic solution, indicating that these antibacterial peptides may take advantage of the more extended form
of bacterial membranes in exerting their killing activities. Additionally, we found that LL37 hemolytic activity
was much higher when RBCs were induced to expose phosphatidylserine to the external leaflet of their plasma
membranes. This finding suggests that asymmetrical distribution of phospholipids in the external membranes
of eukaryotic cells may represent an important factor in determining the specificity of antibacterial peptides
for targeting bacteria rather than eukaryotic cells.
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PBP 10, an antibacterial, cell membrane-permeant rhodamine B-conjugated peptide derived from the
polyphosphoinositide binding site of gelsolin, interacts selectively with both lipopolysaccharides (LPS) and
lipoteichoic acid (LTA), the distinct components of gram-negative and gram-positive bacteria, respectively.
Isolated LPS and LTA decrease the antimicrobial activities of PBP 10, as well as other antimicrobial peptides,
such as cathelicidin-LL37 (LL37) and mellitin. In an effort to elucidate the mechanism of bacterial killing by
PBP 10, we compared its effects on artificial lipid bilayers and eukaryotic cell membranes with the actions of
the mellitin, magainin II, and LL37 peptides. This study reveals that pore formation is unlikely to be involved
in PBP 10-mediated membrane destabilization. We also investigated the effects of these peptides on platelets
and red blood cells (RBCs). Comparison of these antimicrobial peptides shows that only mellitin has a toxic
effect on platelets and RBCs in a concentration range concomitant with its bactericidal activity. The hemolytic
activities of the PBP 10 and LL37 peptides significantly increase when RBCs are osmotically swollen in
hypotonic solution, indicating that these antibacterial peptides may take advantage of the more extended form
of bacterial membranes in exerting their killing activities. Additionally, we found that LL37 hemolytic activity
was much higher when RBCs were induced to expose phosphatidylserine to the external leaflet of their plasma
membranes. This finding suggests that asymmetrical distribution of phospholipids in the external membranes
of eukaryotic cells may represent an important factor in determining the specificity of antibacterial peptides
for targeting bacteria rather than eukaryotic cells.
Antimicrobial peptides are gene-encoded host-derived mol-
ecules that provide a first line of defense against gram-negative
and gram-positive bacteria, fungi, mycobacteria, and some en-
veloped viruses (44, 45). They are found in all species, ranging
from protozoa to vertebrates. Generally, they contain 15 to 45
amino acid residues with a net positive charge (lysine or argi-
nine rich) and are amphipathic (46). After targeting bacterial
membranes, their killing action is faster than the bacterial
growth rate, which accounts for the large antibacterial effect
(4). However, our understanding of the peptide-mediated bac-
terium-killing mechanism is still incomplete. Many of these
peptides are believed to specifically kill bacteria by directly
interacting with and disrupting the negatively charged bacterial
membrane (36, 46). Two general mechanisms, “barrel stave”
and “carpet” (31), have been proposed to describe the process
of phospholipid membrane permeation by membrane-active
peptides. According to the “barrel stave model,” as few as
three molecules are required to induce a membrane pore. To
allow pore formation, the inserted molecules should have dis-
tinct structures, like amphipathic -helices. On the other hand,
according to the “carpet model,” peptides bind to the phos-
pholipid membrane surface until a threshold concentration is
reached and only then permeate it in a detergent-like manner
(17, 31). Antimicrobial peptides might also act through mech-
anisms other than bacterial-membrane destabilization. In ad-
dition to its bactericidal activity, LL37 activates airway epithe-
lial cells, followed by release of interleukin-8 (41). LL37 also
affects the toxicity of bacterium-derived factors, neutralizing
lipopolysaccharide (LPS) bioactivity (20). Cecropin P1 and
PR-39 peptides from the pig small intestine have been shown
to prevent bacterial protein and DNA synthesis (5). The anti-
microbial peptides magainin II and temporins (B and L) were
found to modulate the hydrolytic activity of secretory phospho-
lipase A2 (47).
Recently, we reported that a cell membrane-permeant rho-
damine B-conjugated peptide based on the phosphatidylinositol-
4,5-bisphosphate (PIP2) binding site of gelsolin (GS 160-169
[rhodamine B-QRLFQVKGRR], named PBP 10) can kill the
gram-negative Escherichia coli and Pseudomonas aeruginosa
and the gram-positive Streptococcus pneumoniae (10). A net
positive charge, short sequence, and ability to cross cell mem-
branes represent features of PBP 10 that bear a major resem-
blance to those of the antibiotic peptides. Circular dichroism
and nuclear magnetic resonance evaluations have shown a
coil-to-helix transition when gelsolin residues 150 to 169 bind
PIP2 (43). The helical structure produces an amphipathic mol-
ecule with positive charges arranged on one face and hydro-
phobic residues on the other (10). Unique properties of PBP
10 include polyphosphoinositide binding due to its cationic
charge and hydrophobicity, which are due in part to the linked
rhodamine B. PBP 10 enters cells passively and can affect many
eukaryotic cellular functions that are dependent on phospho-
inositide signaling, most significantly, actin organization and
vesicle trafficking (3, 9, 12, 16).
In exploring mechanisms to explain the bacterium-killing
activity of PBP 10, we compared the effect of PBP 10 on
artificial membranes with the action of the pore-forming pep-
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tides mellitin and magainin II, as well as with the “carpet-like”
membrane-covering LL37 peptide (28). This study shows that
PBP 10 does not form pores during membrane destabilization.
The abilities of LPS and lipoteichoic acid (LTA) to inhibit the
antibacterial activities of all tested peptides, including PBP 10,
suggests that these molecules represent specific bacterial tar-
gets recognized by antibacterial peptides. We have also inves-
tigated the effects of PBP 10, LL37, magainin II, and mellitin
on platelet function and red blood cell (RBC) membranes.
Among these peptides, only mellitin has a toxic effect on plate-
lets and RBCs at a concentration similar to that at which it kills
bacteria.
MATERIALS AND METHODS
Materials. Magainin II (M-7402), synthetic mellitin (M-4171), L--phosphati-
dylcholine (PC) (P-6638), L--phosphatidyl-L-serine (P-6641), sodium dithionite
(S-256), thrombin (T-6884), calcium ionophore A23187 (C-7522), fatty-acid-free
bovine serum albumin (A6003), apyrase (A-6535), Sepharose CL-2B (CL-2B-
300), Sephadex G-75 (G-75-120), and Fura 2-AM (A-9210) were obtained from
Sigma. Brain phosphatidylinositol-4,5-bisphosphate, triammonium salt (840046),
and Escherichia coli total lipid extract (100500) were obtained from Avanti Polar
Lipids. p-Xylene-bis-pyridinium bromide (DPX) (X-1525) and 8-aminonaphtha-
lene-1,3,6-trisulfonic acid (ANTS), disodium salt (A-350), were obtained from
Molecular Probes. LL37 was synthesized using an automatic peptide synthesizer
at the Louisiana State University Medical Center Core Laboratories. The quality
of the obtained peptide was monitored by mass spectrometry and capillary
electrophoresis. The set of gelsolin-related peptides, including QRL and QRLF
QVKGRR, were prepared either as free peptides or conjugated to rhodamine B
with an amide link at the N terminus of the peptide (denoted with RhB- as a
prefix to the peptide sequence) as previously described (12).
Interaction of LTA with fluorescent peptides derived from the gelsolin PIP2
binding site. The fluorescence of rhodamine B-QRLFQVKGRR (Iem, 590 nm;
Iex, 560 nm) was measured 15 minutes after the addition of various concentra-
tions of LTA (from Staphylococcus aureus [Sigma]), LPS (Escherichia coli sero-
type O26:B6 [Sigma]), PIP2, or phosphatidylethanolamine (PE) to 2 M peptide
solutions (PBP 10 or RhB-QRL) in buffer A (10 mM TRIS, 10 mM MES
[morpholineethanesulfonic acid], pH 7.0). Because the quantum yield of rhoda-
mine B is higher in a lipophilic environment, binding of the peptide to a mem-
brane changes rhodamine B fluorescence.
Bactericidal assay. A single colony each of gram-negative Escherichia coli
(kanamycin-resistant SG 13009 or MG1655) and gram-positive Bacillus subtilis
(ATCC 6051) was selected from a plate and grown to mid-log phase (optical
density at 600 nm [OD600], 0.3) in 5 ml of LB (Becton-Dickinson, Cockeysville,
MD) in a shaking incubator (300 rpm; 37°C). One milliliter of the bacterial
suspension was centrifuged at 4,000 rpm for 5 min at room temperature, and the
bacterial pellet was resuspended in phosphate-buffered saline. This suspension
was diluted 1:1,000. Serial dilutions of antibacterial peptides were mixed with the
diluted bacterial suspension, with or without different lipids (LPS, LTA, PIP2,
PC, phosphatidylserine [PS], or bacterial-lipid [BL] extract from Escherichia
coli). The tubes were incubated at 37°C for 1 hour and transferred to ice.
Duplicate 10-l aliquots of 10-fold dilutions (undiluted, 1:10, 1:100, and 1:1,000)
of these mixtures were plated on sectors of LB agar plates, and the plates were
incubated overnight at 37°C. The number of colonies in the duplicate samples at
each dilution was determined the following morning, and the numbers of CFU
in the individual mixtures were determined from the dilution factor. The MIC of
PBP 10 was determined by a broth microdilution method with Mueller-Hinton
(MH) broth according to the procedures outlined by the CLSI (Formerly NCCLS)
(18). A series of twofold dilutions of PBP 10 in MH broth was prepared from a
stock solution and placed in 96-well plates, and then a dilution of bacteria (grown
in half-concentrated MH broth) was added. After incubation for 18 h at 37°C, the
MIC was read (OD600) as the lowest concentration of PBP 10 (g/ml) resulting
in inhibition of visible bacterial growth.
LUV preparation. Lipids dissolved in chloroform were transformed into dry
lipid film by solvent evaporation under a stream of nitrogen. In the next step,
they were kept under vacuum for 3 h, and then the dry lipid film was hydrated
and vortexed. The suspension was freeze-thawed 5 times and then extruded 11
times through polycarbonate filters (100 nm for large unilammelar vesicles
[LUVs] used in phospholipid redistribution assays and 200 nm for ANTS leakage
assays). The LUV size (hydrodynamic diameter) was determined by dynamic
light scattering (DLS). The LUV phospholipid composition was determined by
thin-layer chromatography analysis (8, 11), and the concentration of the resulting
preparation was determined by phosphorus analysis (1).
Redistribution of NBD phospholipids. LUVs were prepared as described above.
1-Oleoyl-2-[6(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino] caproyl (NBD)-PC was in-
corporated in the outer leaflet by adding NBD-PC dissolved in ethanol, at a ratio of
1 to 100 NBD-PC–unlabeled PC, to LUVs in a stirred suspension. Vesicles (100
nmol lipid/ml) were incubated for 60 min at room temperature for equilibration. To
evaluate the flip-flop rate of PC-NBD in PC LUVs in the presence of the magainin
II, LL37, and PBP 10 peptides, we used a technique described by Matsuzaki et al.
(22). The LUVs were incubated with peptides for 30 min at 37°C and placed in a
cuvette of an LS-5B spectrofluorometer (Perkin-Elmer). When required, trypsin was
added for the last 5 min of the incubation period. The NBD fluorescence was
recorded (Iex  470 nm; Iem  540 nm) until a constant baseline (F0) was obtained.
Detection of the NBD-PC present in the LUV’s inner leaflet was monitored after
reduction of the NBD groups of the analogs present in the outer leaflet by dithionite
ion, resulting in a loss of fluorescence intensity due to the conversion of the NBD
group to its seven-amino derivative. Once the decrease in fluorescence emission
caused by the addition of dithionite (10 mM) to the intact LUVs reached a plateau
value (F1), Triton X-100 (1%) was added to expose any NBD-PC protected in the
inner leaflet and to provide the basal fluorescence signal (F2). The fraction of
NBD-PC redistributed into the inner leaflets of LUVs was calculated from the
expression (F1  F2)/(F0  F2).
ANTS leakage assay. For the ANTS/DPX leakage assay, LUVs were prepared
as described above. The dry phospholipid film was hydrated with buffer B (12.5
mM ANTS, 45 mM DPX, 22.5 mM NaCl, 10 mM glycine, 10 mM HEPES, pH
7.4). Following the extrusion process, liposomes were separated from unencap-
sulated material on a Sephadex G-75 column. DPX is highly water soluble, and
when coencapsulated with ANTS, it efficiently quenches ANTS fluorescence by
collisional transfer. The liposomes initially containing both ANTS and DPX emit
about 4% of the fluorescence of the liposomes treated with Triton X-100, which
is assumed to produce 100% leakage (14). Changes in the fluorescence of 1.5 ml
ANTS/DPX LUV samples (2 M phospholipid concentrations) were monitored
with an SLM-Aminco MC200 fluorometer set at an Iex wavelength of 380 nm and
an Iem wavelength of 530 nm for 10 min after the addition of the peptides.
Measurement of vesicle diameter. The LUV sizes (hydrodynamic diameters)
were determined by DLS using a DynaPro 99 instrument. The method measures
the diffusion constant of the vesicles using the autocorrelation function of scat-
tered-light intensity, and the diameter of the vesicle is calculated from the
relation D  kT/6 Rh, where D is the translational diffusion constant, k is
Boltzmann’s constant, T is temperature,  is the solvent viscosity, and Rh is the
hydrodynamic radius. To determine if the LUVs’ phospholipid flip-flop or ANTS
leakage is related to liposome size changes (indicating vesicle fusion or disrup-
tion), LUVs treated with peptides were measured by DLS before and after lipid
redistribution or ANTS leakage assays.
Isolation of human platelets, platelet aggregation, and membrane integrity.
Freshly donated blood from healthy volunteers was collected in acid-citrate
dextrose. Platelet-rich plasma was obtained after centrifugation (15 min; 110 	
g; room temperature) of blood supplemented with apyrase (0.5 U/ml). The
platelets were sedimented by centrifugation (10 min; 1,000 	 g), suspended in
buffer C (139 mM NaCl, 2.8 mM KCl, 0.8 mM MgCl2, 0.8 mM KH2PO4, 8.9 mM
NaHCO3, 10 mM HEPES, 5.6 mM glucose, 0.3% albumin, pH 7.35), and filtered
on a 50-ml column of Sepharose 2B equilibrated with the same buffer. The cell
count was determined using a Z2 Coulter particle counter and size analyzer. To
conduct the aggregation assay, 1-ml samples of 2 	 108 platelets per ml in buffer
C containing 2 mM CaCl2 were introduced into a prewarmed cuvette (37°C) of
a Chronolog Lumi-Aggregometer (Chrono-Log Corp., Havertown, PA). Aggre-
gation was initiated by adding human thrombin and stirring the mixture at 1,000
rpm. Changes in light transmission were recorded using a PowerLab/200 instru-
ment and MacLab Chart program version 3.2. When required, the platelet
suspension was preincubated with antibacterial peptides before platelet aggre-
gation was induced. Platelets labeled with the fluorescent indicator dye Fura-2
according to the method of Pollock et al. (34) and resuspended in buffer C
containing 2 mM CaCl2 were used to measure platelet membrane integrity in the
presence of different antibacterial peptides. Changes in fluorescence were mon-
itored with an SLM-Aminco 8100 fluorometer set at an Iex of 340 nm and an Iem
of 510 nm.
Red blood cell osmotic fragility and hemolysis. A turbidity shift (cloudy to
clear) occurs in a suspension of RBCs when the integrity of the plasma mem-
brane is compromised. This change was detected by optical density at 625 nm
after RBCs, obtained by centrifugation of heparinized blood (1,300 	 g; 10 min;
4°C), washed three times in buffer D (140 mM NaCl, 10 mM HEPES, 5 mM
glucose, 0.1 mM EGTA, pH 7.4), and pretreated with antibacterial peptides,
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were added to hypotonic Ringer solution (21). A percent hemolytic index (HI)
was calculated using the following formula: HI (%)  100 	 (OD of tested
compound  OD of negative control)/(OD of positive control  OD of negative
control). RBCs suspended in deionized water were used as a positive control.
The hemolytic activities of the peptides against RBCs were tested as described
previously (27). Peptides dissolved in phosphate-buffered saline were added to
100 l of RBCs (hematocryt, 5%), and incubation was continued for 1 h at
37°C. The samples were then centrifuged at 1,300 	 g for 10 min. Release of
hemoglobin as a measure of hemolysis was monitored by measuring the absor-
bance of the supernatant at 540 nm. One hundred percent hemolysis (positive
control) was taken from samples in which 1% Triton X-100 was added. When
required, RBCs were activated with 4 M calcium ionophore (A23187) in the
presence of 2 mM CaCl2 or 0.1 mM EGTA (control sample) for 20 min at 37°C.
Phosphatidylserine exposure in A23187-activated RBCs was evaluated using an
annexin V-fluorescein isothiocyanate binding test (data not shown).
RESULTS
LTA interaction with gelsolin polyphosphoinositide binding
sequence. In addition to the previously described interaction of
the PBP 10 peptide with PIP2 and LPS (7, 9), fluorescence
measurements showed an interaction between LTA and PBP
10. The effect of LTA on the fluorescence of PBP 10 is shown
in Fig. 1. As previously reported, upon interaction of LPS with
PBP 10, there was an initial decrease in fluorescence at low
LPS/peptide ratios; the peptide fluorescence increased strongly
with increasing LPS, suggestive of insertion of the peptide-
bound rhodamine B into a more hydrophobic environment (7).
At the molar ratios tested, only the first stage of lowered
fluorescence was seen with LTA or PIP2, and no change was
seen after the addition of PE. There was also no significant
fluorescence change after the addition of LTA to a control
peptide with the sequence rhodamine B-QRL (RhB-QRL)
(data not shown).
Bactericidal activity. By using a standard bacterium-killing
assay, we compared the antimicrobial activities of the naturally
occurring antibacterial agents mellitin and LL37 peptide and
the synthetic rhodamine B-labeled derivative of the PIP2 bind-
ing site of gelsolin by themselves and after their preincubation
with LPS, LTA, PIP2, PC, PS, and an extract of BL from
Escherichia coli (Fig. 2). Previous reports indicated that LPS
could interfere with the antimicrobial activities of different
cathelicidin-LL37 derivates (2). Similarly, we found that LPS
and LTA are powerful inhibitors of the antibacterial activities
of the LL37, mellitin, and PBP 10 peptides against Escherichia
coli SG 13009, Bacillus subtilis ATCC 6051 (Fig. 2), and Esch-
erichia coli MG1655 (data not shown). In the case of PBP 10,
the effectiveness of PIP2 was similar to that of LPS (Fig. 2A).
Under the same conditions PC, PS, and BL did not signifi-
cantly affect the number of growing colonies. The MICs of the
PBP 10 peptide, considered to be the lowest PBP 10 concen-
trations at which observable growth of Escherichia coli
SG13009 and Bacillus subtilis ATCC 6051 was inhibited, were
12.5 and 3.125 g/ml, respectively. These values are in the
range previously determined for other membrane-active pep-
tides (18). Similar MICs and killing values for the PBP 10
peptide against the bacteria tested indicate that a threshold
concentration of PBP 10 is necessary for antibacterial activity
and that once this concentration is reached, PBP 10 causes
bacterial death. This behavior is consistent with the mecha-
nisms of action of other membrane-active antibacterial mole-
cules (37).
Phospholipid flip-flop in asymmetrically labeled PC/PC-
NBD vesicles. We evaluated the flip-flop rates of PC-NBD in
PC LUVs after the addition of magainin II, LL37, and PBP 10.
Figure 3 shows that only magainin II (a pore-forming peptide
digestible by trypsin) (25) induced LUV membrane phospho-
lipid redistribution to a significant extent (45%). The interac-
tion of antibacterial peptides with LUVs prepared from BL
results in vesicle aggregation (Fig. 4B), which interferes with
the NBD-analog redistribution assay, preventing the investiga-
tion of peptide-mediated phospholipid redistribution in BL
vesicles.
Vesicle leakage assay. Pore formation and membrane dis-
ruption would be expected to allow the leakage of small mol-
ecules from lipid vesicles. By using LUVs containing a mixture
of ANTS and DPX, we were able to evaluate the leakage of
ANTS fluorophore, which indicates membrane damage caused
by antibacterial peptides. Figure 4 shows that the PBP 10
peptide can damage vesicles composed of either PC or BL, but
only at concentrations 5 to 10 times higher than those required
to ensure its Escherichia coli-killing property (Fig. 2). Also, the
percentage of LUVs damaged by PBP 10 was much lower than
the damage caused by mellitin, LL37, or magainin II. The
percentages of ANTS leakage from PC and BL were similar.
The efficiencies of equimolar concentrations of antibacterial
peptides decreased in the sequence mellitin 
 LL37 
 ma-
gainin II 
 PBP 10 and were not significantly different in PC
and BL vesicles, supporting the concept that the membrane-
destabilizing effects of these antibacterial agents are not spe-
cifically related to the membrane phospholipid composition.
Effects of antibacterial agents on platelets and red blood
cells. The resting state and thrombin-mediated activation of
platelets are both altered by perturbations of the plasma mem-
brane and provide a sensitive system by which to detect the
effects of amphipathic peptides. The leakage of hemoglobin
from RBCs provides an independent quantitative assay of the
extent of membrane permeabilization. Neither the resting state
of platelets nor platelet aggregation induced by thrombin was
FIG. 1. LTA and LPS bind to PBP 10. Changes in PBP 10 rhoda-
mine B fluorescence in the presence of different lipids (PE, squares;
PIP2, triangles; LPS, diamonds; LTA, circles) indicate its specific in-
teraction with PIP2, LPS, and LTA. The data shown are means or
means  standard deviations of two to four experiments. AU, arbitrary
units.
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FIG. 2. Bactericidal activities of (A and D) PBP 10, (B and E) LL37, and (C and F) mellitin (all squares) against gram-negative Escherichia
coli SG13009 (A to C) and gram-positive Bacillus subtilis ATCC 6051 (D to F) by themselves and their inhibition in the presence of increasing
concentrations of LPS (circles), LTA (open triangles), or PIP2 (squares with dots). Other membrane phospholipids have limited or no effect (PS,
filled triangles; PC, filled circles; BL, diamonds). The data shown are means  standard deviations of three to five experiments.
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affected by preincubation of platelet suspensions with ma-
gainin II or LL37 (Fig. 5A). The possibility that these peptides
may disrupt eukaryotic cell membranes was also tested in ex-
periments in which calcium influx across the plasma membrane
was detected after Fura-2-labeled platelets were mixed with
the LL37 peptide (Fig. 5B) and by evaluating hemoglobin
release from RBCs (Fig. 6). Both assays showed no significant
effect of either LL37 or magainin II at a concentration suffi-
cient to kill bacteria with high efficiency.
In contrast to their tolerance of LL37 and magainin II,
RBCs and platelets were significantly damaged by mellitin.
The increased light transmission of platelet suspensions fol-
lowing the addition of mellitin in the absence of thrombin
suggests platelet lysis (Fig. 5A), the change in the fluorescence
of Fura-2-labeled platelets (Fig. 5B) shows the entry of extra-
cellular Ca2, and the nearly total hemoglobin release from
RBCs (Fig. 6A) results from red blood cell lysis. PBP 10 in-
duced negligible increases of Fura-2-labeled platelet fluores-
cence and hemoglobin release from RBCs, similar to the ef-
fects of the LL37 peptide and magainin II (Fig. 5B and 6). A
disruptive effect of LL37 and PBP 10 on red blood cells was
observed only in RBCs activated with calcium ionophore in the
presence of sufficient calcium to induce plasma membrane PS
exposure (6) in isotonic buffers. Increased hemoglobin release
FIG. 3. Flip-Flop of LUV phospholipid after addition of PBP 10
(open squares), LL37 (filled squares), LL37 plus trypsin (open dia-
monds), magainin II (filled diamonds), and magainin II plus trypsin
(filled triangles) evaluated by monitoring NBD-PC redistribution. PC
LUVs were labeled with 1% NBD-PC in the outer monolayer. After
the addition of peptides, the LUVs were incubated for 30 min at 37°C.
The amount of NBD-PC flipped to the inner monolayer was deter-
mined by dithionite assay. The data shown are means  standard
deviations of three or four experiments.
FIG. 4. Comparison of leakage of ANTS/DPX containing PC (A) and BL (B) liposomes induced with PBP 10 (filled triangles), LL37 (circles),
mellitin (slashed squares), and magainin II (open diamonds). LUVs were prepared by lipid extrusion using 200-nm filters. Changes in their sizes
during the leakage assay were monitored by DLS and are presented as average hydrodynamic radii for PC (C) and BL (D) LUVs. An increase
in the hydrodynamic radius indicates vesicle aggregation. Each data point represents the mean of two experiments.
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(40%), observed after adding LL37 peptide to calcium-iono-
phore-activated RBCs (Fig. 6C), suggests that the presence of
negatively charged phospholipids in the external leaflets of
plasma membranes increases the bioactivity of LL37. This ob-
servation also suggests that phospholipid asymmetry of the
eukaryotic plasma membrane is one of the factors that deter-
mines the low toxicity of antimicrobial peptides against host
cells compared to that against bacteria. When RBCs are mod-
erately swollen by decreasing the osmolarity of the medium,
PBP 10 and, to a greater extent, LL37 begin to exhibit a
significant ability to destroy membrane integrity. As shown in
Fig. 6D, LL37 significantly increases hemolysis at concentra-
tions above 0.5 M in hypotonic solution, and PBP 10 is sig-
nificantly lytic at 5 M. This observation suggests that these
antibacterial peptides may take advantage of the more ex-
tended form of bacterial bilayer membranes in exerting their
antibiotic function.
DISCUSSION
In order to better understand the principles governing the
interactions of antibacterial peptides with target microbes and
host cells, we conducted several experiments to compare the
effects of the synthetic peptide derivative PBP 10 on biological
membranes to those of the natural bioactive peptides LL37,
magainin II, and mellitin. All of the peptides were found to
have significant bactericidal activities, but their abilities to
damage artificial and eukaryotic membranes differed greatly
from each other. Membrane permeabilization and cell lysis
occurring as a result of peptide interaction with membrane
phospholipids may represent a mechanism by which antibac-
terial peptides exert their killing actions; however, the coexis-
tence of additional mechanisms, such as effects on other bac-
terial-cell components or metabolic pathways (32), cannot be
ruled out.
Based on data indicating specific interactions of the PBP 10
peptide with LPS and LTA and the inhibitory effects of LPS
and LTA on bacterium-killing activity by PBP 10, LL37, and
mellitin, two hypotheses can be proposed. First, the presence
of LPS and LTA in external bacterial membranes can specif-
ically attract these peptides, increasing peptide adsorption to
the bacterial surface (24, 31, 38). In this context, LPS and LTA
are the bacterial targets, mediating the peptide’s entry into
bacteria, the initial step of the bacterium-killing cascade (30).
It is also possible that the specific membrane structures formed
by LPS or LTA in association with other bacterial-wall mole-
cules form binding sites for antibacterial peptides (24). The
second hypothesis suggests an opposite role for bacterial-mem-
brane components, i.e., that LPS and LTA represent the first
line of bacterial defense against host antibacterial peptides.
Inhibition of antibacterial peptides by molecules released
from growing or dead bacteria may have a clinical significance,
especially when bacterial infection takes place in the airways or
oral cavity or on the skin surface, the areas in which antibac-
terial peptides are normally active (4, 40). On a molar basis,
LPS as an inhibitor of LL37 and mellitin is much stronger than
any other lipid bilayer constituent from gram-negative bacteria
or eukaryotic cells, including PS, PIP2, or a mixture of bacterial
phospholipids that is rich in PE but devoid of LPS. Only LTA,
the acid glycolipid from the outer membranes of gram-positive
bacteria, has similar inhibitory effects under the conditions
assayed (Fig. 2). The partial inhibition by PS and PIP2 confirms
the primarily electrostatic nature of the interaction that inac-
tivates LL37 and mellitin, but the higher affinities of LPS and
LTA suggest some specificity. The reported resistance to an-
FIG. 5. Human platelet aggregation induced by 1 U/ml of thrombin
in the presence of PBP 10, LL37, magainin II, and mellitin.
(A) Changes in light transmission in platelet suspensions after adding
1 U/ml thrombin (filled circles), 5 M mellitin (filled squares), 5 M
magainin II (followed by thrombin addition; open diamonds), and 5
M LL37 peptide (followed by thrombin addition; open circles).
(B) Changes in fluorescence in Fura-2-labeled platelets indicate Ca2
influx after 1-U/ml thrombin stimulation (filled circles), addition of
0.25 M or 1 M mellitin (slashed and filled squares, respectively),
addition of 1 M or 5 M LL37 (circles with dots and empty circles,
respectively), and addition of 20 M RhB-QRLFQVKGRR peptide
(filled triangles). The data shown in panels A and B were obtained in
a single experiment. Two other experiments produced similar data.
A.U., arbitrary units.
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tibacterial peptides in Salmonella and Staphylococcus strains
has been related to variations in the chemical compositions of
LPS and teichoic acids present in gram-negative and gram-
positive bacterial cell walls, respectively (19, 33).
The observed increase in hemolytic activity of the LL37
peptide against RBCs that expose PS (Fig. 6) confirms the
importance of electrostatic interactions between antibacterial
peptides and phospholipids. In resting cells, phospholipids are
distributed asymmetrically over both halves of the cell plasma
membrane (13, 26), with PS and PE essentially located in the
inner leaflet. This membrane asymmetry may be one factor
allowing the lower lytic activities of antibacterial peptides
against eukaryotic cells than against bacteria. The observed
hemolytic effect of LL37 against RBCs that expose PS supports
the hypothesis that the interaction of cationic antibiotics with
the cell surface is regulated by exposed charges rather than the
electronegative transmembrane gradient pointing toward the
cell interior. In this context, cancer cells and vascular endothe-
lial cells in tumors that expose PS (42, 48) may represent
specific targets for host antibacterial peptides.
Rapid flip-flop of membrane lipids triggered by pore-form-
ing peptides is a well-characterized phenomenon, and lateral
diffusion along the wall of the pores composed of the peptides
and the lipids has been proposed as a model to explain this
process (15, 22, 23). The effects of the PBP 10 and LL37
peptides on phospholipid redistribution (5 to 10% of PC-NBD
redistribution) are unlikely to be induced by pore formation
because of their low rates, and they probably result from pep-
tide penetration into the bilayer rather than from pore forma-
tion. Our previous data show that PBP 10 can induce signifi-
cant PC-NBD redistribution in LUVs containing PIP2 (9) but
not in vesicles lacking phosphoinositides. Additionally, com-
parison of the results from experiments to evaluate phospho-
lipid flip-flop with the results of peptide-mediated ANTS leak-
age revealed that magainin II-induced flip-flop of membrane
phospholipids occurred at a peptide concentration threefold
lower than that required for significant ANTS leakage, in
agreement with previous reports (32). Similarly, PBP 10 lacks
the ability to form pores, since the fluorescence of Fura-2 (a
Ca2 indicator) in platelet cytosol did not change in the pres-
ence of extracellular calcium after the addition of PBP 10.
With regard to hemolytic activity, previous research has
shown that many antibacterial peptides are able to lyse RBCs,
but usually their lytic concentrations are high compared to
FIG. 6. Effects of PBP 10, LL37, magainin II, and mellitin peptides on RBCs. (A) Hemoglobin release from human red blood cells after the
addition of mellitin (squares), magainin II (open diamonds), or calcium ionophore (triangles). (B and C) Hemoglobin release from RBCs after
the addition of PBP 10 and LL37 peptides, respectively. In this experiment, RBCs were preincubated in the presence of EGTA (circles), calcium
(diamonds), A23187 plus EGTA (triangles), or A23187 plus calcium (squares) for 20 min at 37°C before the peptides were added. (D) HI
indicating osmotic fragility of red blood cells in the presence of LL37 (circles) and PBP 10 (triangles), measured as a change in the optical density
at 625 nm in isotonic (open circles and open triangles) and hypotonic (filled circles and filled triangles) buffers. The data shown are means 
standard deviations of four or five experiments.
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their bacterium-killing concentrations (29, 35). We found that
antimicrobial peptides that do not damage human cells in
isotonic solutions could be rendered hemolytic under hypo-
osmotic conditions that by themselves stress but do not per-
meabilize the cell membrane. Red blood cell ghosts prepared
in hypotonic solution preserve their membrane skeletons (39),
suggesting that mechanical stretching of the membrane, which
induces an increase in RBC membrane tension under hypo-
osmotic conditions, facilitates membrane distortion in the
presence of antibacterial peptides.
In conclusion, we have shown that a synthetic peptide, PBP
10, derived from the phosphoinositide-binding site of gelsolin,
like natural antibacterial peptides, targets the bacterial-cell
wall due to interactions with LPS and LTA. The osmotic con-
ditions under which antibacterial peptides function can mod-
ulate their efficiencies. Host cells that expose negatively
charged phospholipids can represent additional targets for an-
tibacterial peptides, indicating their involvement in tissue elim-
ination of apoptotic or necrotic cells.
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